RMRobert W. Massof

Robert W. Massof

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert W. Massof has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psychophysics and the measurement of sensation magnitudes

    by Robert W. Massof, William P. Fisher

  • Open Access

    An Adaptive Strategy for Measuring Patient-Reported Outcomes: Incorporating Patient Preferences Relevant to Cost-Benefit Assessments of Vision Rehabilitation

    by Robert W. Massof, Chris Bradley

    Vision rehabilitation aims to improve daily functioning in patients with chronic disabling vision impairments – low vision – by providing vision assistive equipment and teaching patients effective use of the equipment; teaching patients adaptations to obviate dependence on vision; modifications of the patient’s environment to improve visibility and increase safety; and psychosocial counseling and education to help patients cope with the stress of impaired vision. The interventions that constitute vision rehabilitation are tailored to each patient’s functional goals and personal preferences. This chapter describes the theory, structure, and mechanics of an adaptive patient-reported outcome measure – the Activity Inventory (AI). The AI was developed to identify each patient’s unique set of functional goals within a hierarchical framework, to specify the cognitive and motor activities (i.e., tasks in different functional domains) the patient customarily performs to achieve his or her personal goals, and to elicit ordinal patient ratings of the importance and difficulty of each goal and the difficulty of relevant subsidiary tasks under goals that meet or exceed defined importance and difficulty criteria. The theoretical assumptions of a Rasch psychometric model that is employed to estimate measures of the patient’s overall visual ability from goal difficulty ratings and ability in each functional domain from task difficulty ratings before and after vision rehabilitation are presented and the results for a large group of low vision patients are reviewed. This chapter then explores the issue of how individual patient preferences must be factored into the outcome measures to determine the utility of functional improvements from vision rehabilitation. A theoretical framework for incorporating the utility of individual vision rehabilitation outcomes is offered and its application to functional outcome data is demonstrated.


  • Patient-Reported Measures of the Effects of Vision Impairments and Low Vision Rehabilitation on Functioning in Daily Life

    by Robert W. Massof

    The quantification of vision impairments dates to the mid-nineteenth century with standardization of visual acuity and visual field measures in the eye clinic. Attempts to quantify the impact of vision impairments on patients’ lives did not receive clinical attention until the close of the twentieth century. Although formal psychometric theories and measurement instruments were well developed and commonplace in educational testing, as well as in various areas in psychology and rehabilitation medicine, the late start applying them to clinical vision research created a vacuum that invited poorly developed and poorly functioning instruments and analytic methods. Although this research is still burdened with legacy instruments, mandates by regulatory agencies to include the patients’ perspectives and preferences in the evaluation of clinical outcomes have stimulated the development and validation of self-report instruments grounded in modern psychometric theory and methods. Here I review the progress and accomplishments of applying modern psychometrics to clinical vision research.


  • Open Access

    Predictors of problems reported on the EQ-5D-3L dimensions among people with impaired vision in northern Portugal

    by Antonio Filipe Macedo, Amanda Hellström, Robert Massof, Hanna Tuvesson, Mikael Rask, Pedro Lima Ramos, Jalal Safipour, Ina Marteinsdottir, Evalill Nilsson, Cecilia Fagerström, et al.

    Background: The EQ-5D index often fails to detect the effect of ophthalmic diseases and sight loss. Investigating predictors of individual EQ-5D health dimensions might reveal the underlying reasons. The aim of this study was to investigate predictors of health dimension ratings obtained with the EQ-5D-3L from participants with impaired vision representing a spectrum of eye diseases. Methods: Observational cross-sectional study with participants recruited at four public hospitals in Portugal. Outpatients with visual acuity of 0.30 logMAR(6/12) or worse in the better-seeing eye were invited to participate. Participants completed two instruments: the EQ-5D-3L (measures participants’ perceived health-related quality-of-life) and the Massof Activity Inventory (measures visual ability–ability to perform vision-related activities). This study used logistic regression models to identify factors associated with responses to the EQ-5D-3L. Results: The study included 492 participants, mean age 63.4 years (range = 18–93), 50% females. The most common diagnosis was diabetic retinopathy (37%). The mean visual acuity in the better seeing eye was 0.65 logMAR (SD = 0.48) and the mean visual ability was 0.62 logits (SD = 2.04), the correlation between the two was r = − 0.511 (p < 0.001). Mobility and self-care were the health dimensions with the fewest problems (1% reported extreme problems), anxiety and depression the dimension with the most problems (24% reported extreme problems). ROC curve analysis showed that the EQ-5D index was a poor predictor of cases of vision impairment whilst visual ability given was a good predictor of cases of vision impairment. Visual ability was an independent predictor of the response for all dimensions, higher ability was always associated with a reduced odds of reporting problems. The odds of reporting problems were increased for females in 3 out of 5 dimensions. Comorbidities, visual acuity and age-category were predictors of the odds of reporting problems for one dimension each. Conclusions: The odds of reporting problems for the five health dimensions of the EQ-5D-3L were strongly influenced by the ability to perform vision-related activities (visual ability). The EQ-5D index showed poor performance at detecting vision impairment. These findings are informative and relevant for the clinic and for research evaluating the impact of eye diseases and disease treatments in ophthalmology.


  • MACUSTAR—Do We Have Accurate and Precise Visual Function Outcome Measures Needed to Conduct a Multicenter Clinical Trial of an Early Treatment for Non-Neovascular Age-Related Macular Degeneration?

    by Robert W. Massof

    MACUSTAR is a multicenter observational study of visual function in patients with non-neovascular age-related macular degeneration (AMD) who represent a spectru

  • Open Access

    Calibration of the Activity Inventory Item Bank: A Patient-Reported Outcome Measurement Instrument for Low Vision Rehabilitation

    by Micaela Gobeille, Chris Bradley, Judith E. Goldstein, Robert Massof

    Purpose: To provide calibrated item measures and rating category thresholds for the Activity Inventory (AI), an adaptive visual function questionnaire, from difficulty ratings obtained from a large sample of new low vision patients at pre-rehabilitation baseline. Methods: Baseline AI (510 items) rating scale data from five previous low vision rehabilitation outcome studies (n = 3623) were combined, and the method of successive dichotomizations was used to estimate calibrated item measures and rating category thresholds. Infit statistics were analyzed to evaluate the fit of the data to the model. Factor analysis was applied to person measures estimated from different subsets of items (e.g., functional domains such as reading, mobility) to evaluate differential person functioning. Results: Estimated item measures were well targeted to the low vision patient population. The distribution of infit statistics confirmed the validity of the estimated measures and the two-factor structure previously observed for the AI. Conclusions: Our calibrated item measures and rating category thresholds enable researchers to estimate changes in visual ability from low vision rehabilitation on the same scale, facilitating comparisons between studies. Translational Relevance: The work described in this paper provides calibrated item measures and rating category thresholds for a visual function questionnaire to measure patient-centered outcomes in low vision clinical research. The calibrated AI also can be used as a patient outcome measure and quality assurance tool in clinical practice.


  • Why Don’t Yellow Night Vision Glasses Work?

    by Robert W. Massof

    Over the years, two things have happened that make night driving increasingly difficult for me: I have grown old and automobile headlights have grown whiter and

  • Open Access

    Validation of an Objective Measure of Dry Eye Severity

    by Sezen Karakus, Esen K. Akpek, Devika Agrawal, Robert W. Massof

    Purpose: We evaluated the validity of a single dry eye severity measure estimated using Rasch analysis from a battery of clinical tests and patient symptoms. Methods: This study included 203 dry eye patients and 51 controls. Administered tests included the Ocular Surface Disease Index (OSDI), tear osmolarity, Schirmer's test, noninvasive break-up time, and ocular surface staining. Each of the 12 OSDI questions and each clinical test was defined to be a separate indicator to estimate a single dry eye severity measure from Rasch analysis. Measures of severity were estimated for each subject (person measures) and measures of sensitivity to severity were estimated for each sign and symptom (indicator measures). Results: The average severity measure for dry eye patients was significantly greater than the average severity measure for controls (−0.39 vs. −1.2, P < 0.001). The distribution of indicator measures was well matched to the distribution of person measures. No indicator carried >10% of the total information about dry eye severity carried by all indicators together. However, the most informative indicators were corneal and conjunctival staining. Conclusions: Our study indicated that there is no single “best” dry eye test. Clinical tests and symptoms should be used in combination to estimate a single dry eye severity measure. Translational Relevance: There is no single “gold standard” testing method for dry eye that correlates with the severity of disease. We propose that Rasch analysis can be used to calculate an objective dry eye severity score from a battery of clinical indicators.


  • Open Access

    Estimates of Incidence and Prevalence of Visual Impairment, Low Vision, and Blindness in the United States

    by Tiffany Chan, David S. Friedman, Chris Bradley, Robert Massof

    Low vision (LV) and blindness are leading causes of disability among US residents.1,2 Updated estimates of the prevalence of blindness and LV were recently reported using population-based studies applied to current US census data.3 However, the incidence of blindness and LV in the United States was formally estimated more than a decade ago using 2000 census data.4-6 More current and detailed estimates are needed to inform policy makers to adequately meet present and growing demands for LV rehabilitation services.


  • Open Access

    A strategy for measuring patient preferences to incorporate in benefit-risk assessment of new ophthalmic devices and procedures

    by R W Massof, C Bradley

    The U.S. Food and Drug Administration recently released guidance documents explaining that measurement of patient preferences should be considered during the pre-market approval process to specify patients' tolerances for risk and perspectives on benefit when assessing the benefit-risk profile of new medical devices. For ophthalmological patients, the typical primary clinical outcome is a visual impairment measure. Especially for surgicallyimplanted devices, the benefit a specified improvement in vision measures must be translated to a patient-specific benefit of the improvement in ability to function in everyday life. We developed, and validated with simulations, a strategy for measuring an individual patient's ability to function and the overall benefit to that patient of specified improvements in functional ability. Our strategy employs Rasch analysis to measure changes in functional ability; multidimensional scaling to measure patient-specific benefits of changes in functional ability; and structural equation modeling to cross-walk patient preferences for functional ability changes to changes in visual impairment measures.